On March 27, 2014 Nordic Nanovector reported that its lead product candidate Betalutin has achieved the two major objectives from the Phase I portion of the ongoing Phase I/II clinical trial (NCT01796171) (Press release Nordic Nanovector, MAR 27, 2014, View Source [SID:1234500623]). The ongoing trial has demonstrated that Betalutin is safe and well tolerated in patients suffering from Non-Hodgkin Lymphoma and that the product has a clinically relevant effect in this patient population.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that the ongoing trial already has demonstrated that Betalutin is safe and well tolerated in patients suffering from Non-Hodgkin Lymphoma" stated Jan A. Alfheim, CEO of Nordic Nanovector.

"We are furthermore excited to note that the product candidate has shown a clinically relevant antitumor effect at all dose levels administered to date."

The positive results from Phase I has enabled the company to establish the dose interval for the Phase II part of the clinical trial, which will assess the efficacy of Betalutin in patients suffering from relapsed Non-Hodgkin Lymphoma.